• Provectus Pharmaceuticals Inc., of Knoxville, Tenn., and its five wholly owned subsidiaries – Provectus Biotech Inc., Provectus Devicetech Inc., Provectus Imaging Inc., Pure-ific Corp. and Xantech Pharmaceuticals Inc. – raised an undisclosed amount of money in an unregistered offering. Each unit sold consisted of the right to receive one share of common stock in up to all five subsidiaries and a warrant to purchase three-fourths of one share of the company's common stock.